ZYMEHealthcare · BiotechnologyThe 14 Wall Street analysts covering Zymeworks, Inc. hold a median 12-month price target of $38 — +32.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 31 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Zymeworks, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (91): The share price has been relatively steady.
Growth (26): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ZYME, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +32.9% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2026 | Truist Securities | Maintains | Buy | $32 → $34 |
| 29 Sept 2026 | Citigroup | Maintains | Buy | $38 → $39 |
| 29 Sept 2026 | Citigroup | Maintains | Buy | — |
| 17 Sept 2026 | Wolfe Research | Initiates | Outperform | — |
| 17 Sept 2026 | Wolfe Research | Initiates | Outperform | — |
| 3 Sept 2026 | JP Morgan | Maintains | Overweight | $31 → $33 |
| 3 Sept 2026 | JP Morgan | Maintains | Overweight | — |
| 26 Aug 2026 | Citigroup | Maintains | Buy | — |
| 26 Aug 2026 | Citigroup | Maintains | Buy | $37 → $38 |
| 26 Aug 2026 | Citizens | Reiterates | Market Outperform | $32 |
| 26 Aug 2026 | Citizens | Reiterates | Market Outperform | — |
| 26 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $51 → $55 |
| 26 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Aug 2026 | B. Riley Securities | Reiterates | Buy | $40 → $44 |
| 10 Aug 2026 | B. Riley Securities | Reiterates | Buy | — |
| 7 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 7 Aug 2026 | Truist Securities | Maintains | Buy | $31 → $32 |
| 7 Aug 2026 | Wells Fargo | Maintains | Overweight | $37 → $40 |
| 7 Aug 2026 | Wells Fargo | Maintains | Overweight | — |
| 5 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ZYME appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Zymeworks, Inc. returned +49.6% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 67% of US stocks
Cheaper than 5% of US stocks
Cheaper than 4% of US stocks
Cheaper than 86% of US stocks
Higher than 2% of US stocks
Higher than 3% of US stocks
Higher than 5% of US stocks
Higher than 30% of US stocks
Higher than 17% of US stocks
Higher than 17% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Zymeworks, Inc. has a market value of $2.1B and an enterprise value of $1.8B.
Revenue in the twelve months to 30 June 2026: $37.1M. The latest quarter shrank 90.6% year on year.
Net income over the same four quarters: −$150.0M, a −404.0% net margin.
Diluted earnings per share, trailing twelve months: $−2.02.
Free cash flow in the twelve months to 30 June 2026: −$120.7M.
Zymeworks, Inc. spent $169.8M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 3.8×; forward P/E: 23.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Zymeworks, Inc. employs 231 people — $161K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Zymeworks, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks says Zymeworks lacks the combination of two key ingredients associated with a likely earnings beat ahead of its upcoming Q3 report. The item says the report’s key expectations are being outlined.
Why it matters — ZYME watchers may note the article’s caution about the likelihood of an earnings beat before the company reports Q3 results.
Zymeworks outlined a partnering-focused research strategy, presented updated ZW191 clinical data in platinum-resistant ovarian cancer, and discussed its recently announced Roche collaboration involving DLL3-targeting T-cell engager ZW209.
Why it matters — The update covers Zymeworks’ clinical progress with ZW191 and a collaboration that forms part of its partnering strategy.
The Seeking Alpha item is a transcript discussing Zymeworks’ portfolio strategy, Roche partnership, and pipeline updates. The excerpt provides no further details about the discussion.
Why it matters — ZYME watchers may find the topics relevant to the company’s strategy, partnership, and development pipeline, though the excerpt contains no specific updates.
Faeth Therapeutics appointed Adam Schayowitz, Ph.D., MBA, to its Board of Directors. Schayowitz is Zymeworks’ Executive Vice President and Head of Research and Development.
Why it matters — The appointment is relevant to Zymeworks watchers because it involves a senior Zymeworks executive taking a board role at another oncology company.
Zymeworks presented new clinical data from the randomized dose-optimization portion of its ongoing Phase 1 study of ZW191, a folate receptor alpha-targeting antibody-drug conjugate, at the ESMO Congress 2026.
Why it matters — The presentation provides an update on clinical development of ZW191, a candidate in Zymeworks’ pipeline.
The 14 Wall Street analysts covering Zymeworks, Inc. have a median 12-month price target of $38, with estimates ranging from $32 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Zymeworks, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zymeworks, Inc. 63 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Zymeworks, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (91 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +32.9% from the last close, and Ticker Nerd's factor model ranks Zymeworks, Inc. 63 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Zymeworks, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZYME are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $60 over the next 12 months.
Zymeworks, Inc. returned +49.6% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Zymeworks Inc. is a biotechnology company focused on discovering, developing, and commercializing multifunctional biotherapeutics for cancer and other serious diseases.
The most recent item we track (Zacks Investment Research, 29 Oct 2026): "Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings Growth". Zacks says Zymeworks lacks the combination of two key ingredients associated with a likely earnings beat ahead of its upcoming Q3 report. The item says the report’s key expectations are being outlined.
Zymeworks Inc. is a biotechnology company focused on discovering, developing, and commercializing multifunctional biotherapeutics for cancer and other serious diseases. The company operates across therapeutic areas including oncology, inflammation, and autoimmune disease, using proprietary antibody-based platforms to design differentiated drug candidates. Its current portfolio includes clinical-stage programs and licensed healthcare assets, supported by integrated research, development, and commercialization capabilities. Zymeworks also works with antibody-drug conjugate technologies and other advanced biologic platforms aimed at improving precision and therapeutic performance across difficult-to-treat conditions. With operations centered on modern drug innovation, Zymeworks Inc. plays a role in advancing next-generation treatments within the global biopharmaceutical market.
CEO Mr. Kenneth H. Galbraith C.A. · 231 employees · United States · https://www.zymeworks.com
